In-silico and Physicochemical Predictions Studies of Piperidine Containing Compounds as Anti-Alzheimer’s Agents
DOI:
https://doi.org/10.22270/ajprd.v14i5.1822Abstract
Background: Alzheimer's disease is a neurodegenerative condition marked by memory decline and reduced acetylcholine levels. The objective of this study was to design and evaluate novel piperidine analogs as potential inhibitors of acetylcholinesterase (AChE) enzyme.
Materials and Methods: From molecular hybridization and pharmacophore optimization technique fifteen new piperidine-hydrazone derivatives were designed. Using AutoDock and AutoDock Vina, molecular docking studies were performed against the AChEenzyme (PDB ID: 4PQE).
Results & Discussion:Based on the comprehensive docking data, compound 12 exhibited the strongest binding affinity with a score of -11.2 kcal/mol. Compounds 1 and 2 also demonstrated highly favourable binding energies of -10.8 kcal/mol and -10.7 kcal/mol, respectively. All of these top candidates significantly outperformed the standard therapeutic drugdonepezil, which displayed score -8.6 kcal/mol. Pharmacokinetic assessments from Lipinski’s rule of fiveand toxicity prediction study supportedtheir anti-alzheimerspotential.
Conclusion: Piperidine-hydrazone scaffold exhibited an optimal balance of flexibility and rigidityenabling simultaneous dual-site inhibition at the enzyme's CAS and PAS. In-silico ADMET prediction study validated thesepiperidine analogs are strong lead candidates for subsequent anti-alzhiemer’s development.
Downloads
References
Alzheimer’s Association, 2023 Alzheimer’s disease facts and figures. Alzheimers Dement.2023; 19:1598–1695.
ChauhanA, Devi R, Singh S et al. Current and emerging therapeutic approaches in Alzheimer’s disease. Discov. Neurosci. 2026; 21:57. https://doi.org/10.1186/s13064-026-00290-5.
Grabowska, W.; Bijak, M.; Szelenberger, R.; Gorniak, L.; Podogrocki, M.; Harmata, P.; Cichon, N. Acetylcholinesterase as a Multifunctional Target in Amyloid-Driven Neurodegeneration: From Dual-Site Inhibitors to Anti-Agregation Strategies. Int. J. Mol. Sci. 2025; 26:8726. https://doi.org/10.3390/ijms26178726.
Abdelshaheed MM, Fawzy IM, El-Subbagh HI. et al. Piperidine nucleus in the field of drug discovery. Futur J Pharm Sci 2021; 7:188https://doi.org/10.1186/s43094-021-00335-y.
Łowicki D, Przybylski P. Piperidine-containing drugs and recently studied analogs – biological activity, mechanism of action and synthetic cascade access to their scaffolds.Eur JMed Chem 2026; 302:118213, Part 1.https://doi.org/10.1016/j.ejmech.2025.118213.
Vemula D, Jayasurya P, Sushmitha V, Kumar YN, Bhandari, V. CADD, AI and ML in drug discovery: A comprehensive review. EurJ Pharm Sci 2023;181:106324.
https://doi.org/10.1016/j.ejps.2022.106324.
Zhang J, Zhang Y, WangJ et al. Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Sig Transduct Target Ther 2024; 9:211 https://doi.org/10.1038/s41392-024-01911-3
Nguyen TH, Tran P-T, Pham NQA, Hoang V-H etal. Identifying Possible AChE Inhibitors from Drug-like Molecules via Machine Learning and Experimental Studies. ACS Omega 2022; 7 (24):20673–20682.https://doi.org/10.1021/acsomega.2c00908
Tok F, Sağlık, BN, Özkay Y, Kaplancıklı ZA, Koçyiğit‐Kaymakçıoğlu B. N‐substituted arylidene‐3‐(methylsulfonyl)−2‐oxoimidazolidine‐1‐carbohydrazideas cholinesterase inhibitors:Design, synthesis, and molecular docking study. Chem Biodiv2022a; 19:e202200265.
https://doi.org/10.1002/cbdv.202200265.
Tok F, Sağlık BN, Özkay Y, Kaplancıklı ZA et al. Design, synthesis, biological activity evaluation and in silico studies of new nicotinohydrazide derivatives as multi-targeted inhibitors for Alzheimer's disease. JMolStruct.2022; 1265:133441.
https://doi.org/10.1016/j.molstruc.2022.133441.
Tok F, Baltaş N, Abas BI, Yılmaz GT et al. Design, synthesis, molecular modeling, in vitro evaluation of novel piperidine-containing hydrazone derivatives as cholinesterase inhibitors. Drug Dev Res 2024; 85(5):e22240. https://doi.org/10.1002/ddr.22240.
Dwivedi KH, Kumar V, Chandrawanshi VK. A Review on the Role of Chemdrawin Facilitating Accurate Molecular & Structural Illustrations. Inter J Creat Res Thoughts.2024; 12:12
Trott O, Olson AJ.AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comb Chem 2010; 31(2):455-461.
O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox. J Chem Inform. 2011; 3:33.
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7:42717.
PiresDEV, Blundell TM, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 2015; 58(9):4066–4072. https:// pymol.org https://www.rcsb.org/strcture/4PQE
Nath R, Bhattacharjee S, Ashique S, Panda S et.al Therapeutic potential of nitrogen-containing heterocyclic compounds in Alzheimer's disease: From molecular design to SAR studies. JMol Struct 2026; 144837:1354.
https://doi.org/10.1016/j.molstruc.2025.144837.
Kumar H, Datusalia, AK, Khatik GL. Virtual screening of acetylcholinesterase inhibitors through pharmacophore-based 3D-QSAR modeling, ADMET, molecular docking, and MD simulation studies. In Silico Pharmacol. 2024; 12:13.
https://doi.org/10.1007/s40203-024-00189-1
Daina A, Zoete, V. A BOILED-Egg to Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. 2016; 11 (11): 1117-1121.
https://doi.org/10.1002/cmdc.201600182
https://biosig.lab.uq.edu.au/pkcsm/
LiverTox: Clinical and Research Information on Drug Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Donepezil. [Updated 2020 Jan 15].
Pathak C, Kabra UD. A comprehensive review of multi-target directed ligands in the treatment of Alzheimer’s disease. Bioorg Chem2024; 144:107152.
https://doi.org/10.1016/j.bioorg.2024.107152
Almaghrabi,M. Multitarget-Directed Ligands for Alzheimer’s Disease: Recent Novel MTDLs and Mechanistic Insights. Pharmaceuticals 2025; 18(11), 1685.
Published
Versions
- 2026-10-15 (2)
- 2026-10-15 (1)
How to Cite
Issue
Section
Copyright (c) 2026 Payal M. Gajare, Atul N. Khadse

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.